Balyasny Asset Management LLC Apellis Pharmaceuticals, Inc. Transaction History

Balyasny Asset Management LLC

$57.8 Billion
Q1 2025

A detailed history of Balyasny Asset Management LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 324,487 shares of APLS stock, worth $6.15 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

324,487

Previous 744,194 56.4%

Holding current value

$6.15 Million

Previous $23.7 Million 70.12%

% of portfolio

0.01%

Previous 0.04%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$21.87 - $34.63 $9.18 Million - $14.5 Million	-419,707 Reduced 56.4%	324,487 $7.1 Million
Q4 2024 Feb 14, 2025	BUY	$26.18 - $35.42 $19.5 Million - $26.4 Million	744,194 New	744,194 $23.7 Million
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $1.23 Million - $1.93 Million	-32,289 Reduced 13.9%	199,954 $7.67 Million
Q1 2024 May 13, 2024	BUY	$55.39 - $72.47 $12.9 Million - $16.8 Million	232,243 New	232,243 $13.7 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $24.1 Million - $29.3 Million	-313,728 Reduced 50.77%	304,169 $27.7 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $16.8 Million - $24.2 Million	361,556 Added 141.04%	617,897 $40.8 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $9.04 Million - $12.8 Million	209,076 Added 442.35%	256,341 $13.3 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $2.12 Million - $3.29 Million	47,265 New	47,265 $3.23 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $4.56 Million - $6.96 Million	-128,514 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $1.68 Million - $2.69 Million	-54,633 Reduced 29.83%	128,514 $6.08 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $5.75 Million - $12.8 Million	183,147 New	183,147 $6.04 Million
Q4 2018 Feb 14, 2019	SELL	$11.47 - $18.71 $688,200 - $1.12 Million	-60,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$16.57 - $21.03 $89,941 - $114,150	-5,428 Reduced 8.3%	60,000 $1.07 Million
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $1.28 Million - $1.96 Million	65,428 New	65,428 $1.44 Million

Others Institutions Holding APLS

# of Institutions

286

Shares Held

124M

Call Options Held

921K

Put Options Held

761K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.08B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Account

Balyasny Asset Management LLC Apellis Pharmaceuticals, Inc. Transaction History